---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053917"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:29:11.214399+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M

## Summary
- Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.
- Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.
- Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.
- FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.
- Cash used in ops $122.6M; total debt $705M at quarter end.

## SEC filing metadata
- accession: 0000950170-24-053917
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/0000950170-24-053917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/md-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053917
- JSON: https://secwatch.observer/filing/0000950170-24-053917.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053917.txt

## Key facts
- Earnings Releases
  Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.
  - Period: the three months ended March 31, 2024
  - Revenue: $495.1 million
  - Net income: $4.0 million
  - EPS: $0.05 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/0000950170-24-053917-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.